You choose, we deliver
If you are interested in this story, you might be interested in others from The Journal Gazette. Go to and pick the subjects you care most about. We'll deliver your customized daily news report at 3 a.m. Fort Wayne time, right to your email.


  • Will new Congress be virus or bacterium?
    Certain drug manufacturers, such as Eli Lilly here in Indiana, rely on live cells, often E. coli bacterial cells, to make life-saving drugs. And this, of course, is a good thing. If chemists had to make all our drugs without cell technologies, some
  • Inconsistencies drove ballot inquiry
    As Allen County Clerk of the Courts and member of the Election Board, I take an oath to do what is right, regardless of politics, appearance, and perception. On Oct.
  • Distrust breeds online literacy
    Does your child know what is fact and what is fiction on the Internet? According to Media Smarts, beginning at age 9 children should know strategies for determining the authorship and authority of online information.
What to do
If a drug you’re taking is not available and you believe it might be in short supply, the FDA recommends taking the following steps:
Visit its shortages page to see whether your drug has been reported as in short supply,
If your drug isn’t on the FDA’s list, send the name and dose of the drug and your contact information to FDA’s Center for Drug Evaluation and Research at
If your medicine is in short supply, talk with your doctor. There might be others that work as well.

FDA strives to minimize lapses in drug supplies

Drug shortages can leave patients and those who care for them scrambling.

The Food and Drug Administration’s most recent proposal to help keep a lid on nationwide drug shortages is a move in the right direction but no cure.

It refines a 2012 rule change, adding definitions of what must be reported and how.

“I don’t see how they could further regulate it” beyond that, said Trent Towne, an infectious disease specialist and assistant professor of pharmacy practice at the Manchester University College of Pharmacy who has lectured on drug shortages.

Towne said he understands where the FDA is coming from, but said there is a sort of Catch-22 involved.

Under the FDA plan made public last week, manufacturers of many medications or biological products – including blood or blood components for transfusion – would be required to notify the FDA of a “permanent discontinuance or an interruption that is likely to lead to a meaningful disruption” in the supply. It wants six months’ notice whenever possible.

Towne said most supply breakdowns are caused by unforeseen circumstances.

Some supply stoppages occur because the business chooses to do so, but most happen because it needs to retool, a component of the medication is not available or the FDA finds something wrong in the production process and orders a shutdown.

Companies, he said, can’t rub a crystal ball and know what they’ll have in six months, or even tomorrow.

If retooling is required in a sterile facility, the process can be lengthy. Even if another manufacturer takes up the slack, it might not be able meet the demand immediately.

As of Monday, FDA’s drug shortage list shows scores of drugs in short supply. Those numbers have decreased dramatically since the 2012 rule change, but that is cold comfort if your medication is on the list now.

Towne said in recent years they have seen shortages in injectable drugs – including generic painkillers and antibiotics – that are made by just a few companies that run on pretty tight margins.

The latest proposal from the FDA has recommended more fully engaging the entire supply chain, all the way from the manufacturer to the patient.

Christopher Topoleski, director of federal regulatory affairs at the American Society of Health-System Pharmacists, said his group is encouraged by the FDA’s reaching out to other stakeholders – including pharmacists, doctors and hospitals.

Although his group has worked with the FDA on shortages for more than a decade, he said this is the first time the agency has included more than manufacturers in a proposed rule.

He said the FDA’s plan is straightforward, spelling out what is covered and making the process of who must report what very clear.

The best weapon we have against shortages is notification in a timely manner, and he said consistent requirements will help.